A polypill containing fixed low doses of three antihypertensive drugs led to better blood pressure (BP) control without increased adverse effects compared with usual care among people with persistent hypertension, according to the TRIUMPH* trial.
Long-term use of febuxostat, a nonpurine xanthine oxidase inhibitor, was associated with higher all-cause and cardiovascular (CV) deaths despite noninferiority to allopurinol in terms of adverse CV events, findings from the CARES* trial showed. This finding raises safety issues regarding the treatment of gout in patients with major CV disease.
Women with a history of pre-eclampsia may be at increased risk of developing cardiovascular (CV) risk factors such as hypertension, diabetes, and hyperlipidaemia later in life compared with women without a history of pre-eclampsia, according to a study presented at ACC.18.
The combination of low-dose rivaroxaban and aspirin reduces the incidence of major adverse limb events (MALE) in patients with stable lower-extremity peripheral artery disease (PAD), a sub-study of the COMPASS* trial has shown.
The use of a non-invasive, wearable cardioverter defibrillator (WCD) in addition to medical therapy did not significantly reduce the incidence of sudden and non-sudden death within 3 months of an acute myocardial infarction (MI), results from the VEST* trial show.
High-dose statin preloading does not cut the 30-day event risk in patients with acute coronary syndrome (ACS) in the SECURE-PCI* study. But in patients with ST-segment elevation MI (STEMI) undergoing percutaneous coronary intervention (PCI), preloading with high-dose atorvastatin reduced the risk of major adverse cardiac events (MACE).
The SGLT2* inhibitor canagliflozin reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D) and high CV risk, according to investigators of the CANVAS** programme presented at the American College of Cardiology Annual Scientific Session & Expo (ACC.18) in Orlando, Florida, US.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.